

Contact Person: Phyllis D. Artis, Grant Technical Assistant, Parklawn Building, Room 9C-26, 5600 Fishers Lane, Rockville, MD 20857, Telephone: 301, 443-6470.

The meetings will be closed in accordance with the provisions set forth in sec. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Numbers 93.126, Small Business Innovation Research; 93.176, ADAMHA Small Instrumentation Program Grants; 93.242, Mental Health Research Grants; 93.281, Mental Research Scientist Development Award and Research Scientist Development Award for Clinicians; 93.282, Mental Health Research Service Awards for Research Training; and 93.921, ADAMHA Science Education Partnership Award.)

Dated: May 3, 1995.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 95-11420 Filed 5-9-95; 8:45 am]

BILLING CODE 4140-01-M

Prospective Grant of Exclusive License: Oncoimmunins

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This notice in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(I) that the National Institutes of Health and Human Services, is contemplating the grant of an exclusive world-wide license to practice the inventions embodied in a U.S. Patent 5,364,619 and U.S. Patent Applications; USSN 07/764,695 and USSN 08/218,023 and corresponding foreign patent applications each entitled, "Oncoimmunins" to Oncoimmunin, Inc. of Kensington, Maryland. The patent rights in these inventions have been assigned to the United States of America.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless within sixty (60) days from the date of this published notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Tumor-infiltrating lymphocytes (TILs) have shown in vivo antitumor efficacy in both animal and human studies. Functions thought necessary for antitumor activity include cytolysis, homing, and proliferation at tumor sites. T-cell mitogens of tumor origin have been suggested to be responsible, in part, for the local stimulation of T-lymphocytes around tumors. Two tumor-derived, soluble proteins named Oncoimmunin-L and Oncoimmunin-M have been isolated and partially characterized. Oncoimmunin-L is a T-cell mitogen and Oncoimmunin-M is a myeloid differentiation inducing agent. The partial characterization of these two factors has shown that they are similar to human leukocyte elastase inhibitor and human lactate dehydrogenase M, respectively. As cells of both lymphoid and myeloid origin are known to play roles in immune defense, factors which can modulate their number and/or function may be useful in the diagnosis and treatment of cancer. Since these factors are derived from tumors, their appearance in blood may signal the presence of tumor or of metastatic disease. The in vivo bioactivities of these factors suggests their utility as therapeutic agents for cancer and infectious diseases.

ADDRESSES: Requests for copies of the patent applications, inquiries, comments and other materials relating to the contemplated licenses should be directed to: Raphe Kantor, Ph.D., Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804. Telephone: (301) 496-7735 ext. 247; Facsimile: (301) 402-0220. A signed Confidentiality Agreement will be required to receive copies of the patent applications. Applications for a license in any field of use filed in response to this notice will be treated as objections to the grant of the contemplated licenses. Only written comments and/or applications for a license which are received by NIH on or before July 10, 1995 will be considered.

Dated: April 24, 1995.

Maria C. Freire,

Director, Office of Technology Transfer.

[FR Doc. 95-11423 Filed 5-9-95; 8:45 am]

BILLING CODE 4140-01-P

Prospective Grant of Exclusive License: Neuro-Derived Fetal Cell Lines for Transplantation Therapy

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive world-wide license to practice the inventions embodied in U.S. Patent 4,707,448, entitled "Immortal Line of Human Fetal Glial Cells," U.S. Patent Application SN 08/046,527 entitled "Use of Neuro-Derived Fetal Cell Line for Transplantation Therapy" and corresponding foreign patent applications to Pro-Virus, Inc. of Rockville, Maryland. The patent rights in these inventions have been assigned to the United States of America.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless within 60 days from the date of this published notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

The patent discloses a novel immortalized fetal glial cell line, designated SVG. The pending patent application discloses the methods of using such cell lines or genetically modified clones thereof for therapeutic purposes to treat various neurological diseases and disorders via transplantation of the cell lines into the patient. Cell lines, such as SVG, have the advantage of being a continually renewable resource and relatively homogenous. Additionally, such cell lines eliminate the significant safety concerns associated with primary human fetal tissue transplants that may harbor opportunistic disease-causing agents and may be subjected to a battery of tests to ensure their safety and efficacy before being used in transplantation.

ADDRESSES: Requests for copies of the patent and the patent applications, inquiries, comments and other materials relating to the contemplated licenses should be directed to: Mr. Arthur J. Cohn, Esq., Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20892-3804. Telephone: (301) 496-7735 ext 284; Facsimile: (301) 402-0220. A signed Confidentiality Agreement will be required to receive copies of the patent applications. Applications for a license in the field of use filed in response to this notice will be treated as objections to the grant of the contemplated

licenses. Only written comments and/or applications for a license which are received by NIH on or before July 10, 1995 will be considered.

Dated: April 26, 1995.

Maria C. Freire,

Director, Office of Technology Transfer.

[FR Doc. 95-11424 Filed 5-9-95; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. N-95-3799; FR-3711-N-03]

Office of the Assistant Secretary for Public and Indian Housing; Announcement of Funding Awards for Technical Assistance to Public Housing Authorities and Public Housing Police Departments

AGENCY: Office of the Assistant Secretary for Public and Indian Housing.

ACTION: Announcement of funding awards.

SUMMARY: According to section 102(a)(4)(C) of the Department of Housing and Urban Development Reform Act of 1989, this document notifies the public of the funding award for Fiscal Year (FY) 1995 Technical Assistance to Public Housing Authorities and Public Housing Police Departments. The purpose of this document is to announce the name and address of the award winner and the amount of the award.

FOR FURTHER INFORMATION CONTACT: Malcolm E. Main, Crime and Prevention Division, Office Community Relations and Involvement, Public and Indian Housing, Department of Housing and Urban Development, Room 4116, 451 Seventh Street, SW., Washington, DC. 20410, telephone (202) 708-1197. A telecommunications device for hearing or speech impaired persons (TDD) is available at (202) 708-0850. (These are not toll-free telephone numbers.)

SUPPLEMENTARY INFORMATION:

I. Authority

This grant is authorized under Chapter 2, Subtitle C, Title V of the Anti-Drug Abuse Act of 1988 (42 U.S.C. 11901 et. seq.), as amended by Section 581 of the National Affordable Housing Act of 1990 (NAHA), approved November 28, 1990, Pub. L. 101-625, and Section 161 of the Housing and Community Development Act of 1992 (HCDA 1992) (Pub. L. 102-550, approved October 28, 1992).

II. Federal Fiscal Year 1995 Funding

The Departments of Veterans Affairs and Housing and Urban Development, and Independent Agencies Appropriations Act 1995, (approved September 28, 1994, Pub. Law 103-327), (95 App. Act) appropriated \$290 million for the Drug Elimination Program. Of the total \$290 million appropriated, \$10 million will fund drug elimination technical assistance, contracts and other assistance training, program assessments, and execution for or on behalf of public housing and resident organizations (including the cost of necessary travel for participants in such training). The funding announced under this notice is a part of this \$10 million.

III. Grant Award

On June 28, 1994, HUD published a Notice of Funding Availability (NOFA) for Technical Assistance to Public Housing Authorities and Public Housing Police Departments (59 FR 33372) announcing the availability of up \$1.5 million in FY 1994 funds for a 1-year base period with 4 option years for comparable amounts based upon an evaluation of grant performance and the availability of funds. The Department reviewed, evaluated and scored the applications received based on the criteria in the NOFAs. As a result, HUD has funded the application announced below. The announcement of the FY 1994 award, in the amount of \$1,499,348, was published on October 20, 1994 (59 FR 52983). This notice announces the award of \$2,000,000 in FY 1995 funding to continue activities for two option years. In accordance with section 102(a)(4)(C) of the Department of Housing and Urban Development Reform Act of 1989 (Pub. L. 101-235, approved December 15, 1989), the Department is publishing details concerning the recipient of this funding award, as follows:

Grant Recipient: Center for Public Safety, Inc.

Recipient Contact Person: Thomas J. Shaughnessy.

Address: Center for Public Safety, Inc., Washington Dulles International Airport, PO Box 20261, Washington, DC 20041-2261.

Telephone Number: (703) 661-2168.

Original Award Amount: \$1,499,348.

Amendment Grant Award Amount: \$2,000,000.

Total Grant Award Amount: \$3,499,348.

General Objectives

The United States Department of Housing and Urban Development (HUD) and the Center for Public Safety, Inc., (grantee) have entered into a grant

agreement for \$3,499,348 of Public and Indian Housing Drug Elimination Program Technical Assistance funds to: (1) Develop a program to improve public housing police departments in Baltimore HA and Community Development, Baltimore, MD; Boston HA, Boston, MA; Buffalo HA, Buffalo, NY; Cuyahoga Metropolitan HA, Cleveland, OH; HA of the City of Los Angeles, Los Angeles, CA; HA of the City of Oakland, Oakland, CA; HA of the City of Pittsburgh, Pittsburgh, PA; HA of the City of Waterbury, Waterbury, CT; Virgin Islands HA, Virgin Islands; Philadelphia HA, and Philadelphia, PA, (2) facilitate law enforcement service agreements between housing authorities and local government, and (3) provide the technical assistance to implement the program and agreements.

This is a cost-reimbursable grant for \$3,499,348 for a three year base period, with two optional years. Each additional fiscal year award will be for comparable amounts based upon an evaluation of grant performance and the availability of funds.

Dated: March 18, 1995.

Joseph Shuldiner,

Assistant Secretary for Public and Indian Housing.

[FR Doc. 95-11440 Filed 5-9-95; 8:45 am]

BILLING CODE 4210-33-P

DEPARTMENT OF THE INTERIOR

Fish and Wildlife Service

Notice of intent to prepare an Environmental Impact Statement for the Proposed Establishment of a National Wildlife Refuge in Georgetown, Horry, and Marion Counties, South Carolina, and Notice of Meetings to Seek Public Participation

AGENCY: Fish and Wildlife Service, Interior.

ACTION: Notice of intent and meetings.

SUMMARY: This notice advises the public that the U.S. Fish and Wildlife Service, Southeast Region, intends to prepare an environmental impact statement (EIS) for the proposed establishment of a national wildlife refuge in Georgetown, Horry, and Marion Counties, South Carolina, and plans to hold two scoping meetings in the vicinity of the proposed refuge to involve the public in the preparation of the EIS.

DATES: The Service will hold two scoping meetings as follows: (1) At 7:00 p.m. on June 20, 1995, at the Georgetown High School Auditorium, Georgetown, South Carolina; and (2) at